Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Stereotactic ablative radiation therapy for brain metastases with volumetric modulated arc therapy and flattening filter free delivery: feasibility and early clinical results

Stereotactic ablative radiation therapy for brain metastases with volumetric modulated arc... Radiol med (2017) 122:676–682 DOI 10.1007/s11547-017-0768-0 NEURORADIOLOGY Stereotactic ablative radiation therapy for brain metastases with volumetric modulated arc therapy and flattening filter free delivery: feasibility and early clinical results 1 1 1 1 Alba Fiorentino · Niccolò Giaj‑Levra · Umberto Tebano · Rosario Mazzola · 1 1 2 1 Francesco Ricchetti · Sergio Fersino · Gioacchino Di Paola · Dario Aiello · 1 1 Ruggero Ruggieri · Filippo Alongi Received: 4 November 2016 / Accepted: 12 April 2017 / Published online: 26 April 2017 © Italian Society of Medical Radiology 2017 Abstract follow-up time of 12 months (range 1–27 months), the Aim For selected patients with brain metastases (BMs), median overall survival was 14 months and the 6-month the role of stereotactic radiosurgery (SRS) or fractionated overall survival was 77%. Finally, the median intracranial stereotactic radiotherapy (SFRT) is well recognized. The disease control was 11 months. Acute and late toxicities recent introduction of flattening filter free (FFF) delivery were acceptable without severe events (no adverse events during linac-based SRS or SFRT allows shorter beam-on- ≥G2 were recorded). time, improving patients’ comfort and facility workflow. Conclusions These preliminary results highlighted the Nevertheless, limited experiences evaluated the impact of feasibility and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png La radiologia medica Springer Journals

Stereotactic ablative radiation therapy for brain metastases with volumetric modulated arc therapy and flattening filter free delivery: feasibility and early clinical results

Loading next page...
1
 
/lp/springer_journal/stereotactic-ablative-radiation-therapy-for-brain-metastases-with-qBz90VvxMO

References (47)

Publisher
Springer Journals
Copyright
Copyright © 2017 by Italian Society of Medical Radiology
Subject
Medicine & Public Health; Imaging / Radiology; Diagnostic Radiology; Interventional Radiology; Neuroradiology; Ultrasound
ISSN
0033-8362
eISSN
1826-6983
DOI
10.1007/s11547-017-0768-0
pmid
28447313
Publisher site
See Article on Publisher Site

Abstract

Radiol med (2017) 122:676–682 DOI 10.1007/s11547-017-0768-0 NEURORADIOLOGY Stereotactic ablative radiation therapy for brain metastases with volumetric modulated arc therapy and flattening filter free delivery: feasibility and early clinical results 1 1 1 1 Alba Fiorentino · Niccolò Giaj‑Levra · Umberto Tebano · Rosario Mazzola · 1 1 2 1 Francesco Ricchetti · Sergio Fersino · Gioacchino Di Paola · Dario Aiello · 1 1 Ruggero Ruggieri · Filippo Alongi Received: 4 November 2016 / Accepted: 12 April 2017 / Published online: 26 April 2017 © Italian Society of Medical Radiology 2017 Abstract follow-up time of 12 months (range 1–27 months), the Aim For selected patients with brain metastases (BMs), median overall survival was 14 months and the 6-month the role of stereotactic radiosurgery (SRS) or fractionated overall survival was 77%. Finally, the median intracranial stereotactic radiotherapy (SFRT) is well recognized. The disease control was 11 months. Acute and late toxicities recent introduction of flattening filter free (FFF) delivery were acceptable without severe events (no adverse events during linac-based SRS or SFRT allows shorter beam-on- ≥G2 were recorded). time, improving patients’ comfort and facility workflow. Conclusions These preliminary results highlighted the Nevertheless, limited experiences evaluated the impact of feasibility and

Journal

La radiologia medicaSpringer Journals

Published: Apr 26, 2017

There are no references for this article.